Paradigm Biopharmaceuticals Ltd
OTC:PBIGF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Paradigm Biopharmaceuticals Ltd
OTC:PBIGF
|
AU |
|
C
|
Cooper Companies Inc
F:CP6
|
US |
|
E
|
Enwave Corp
XBER:E4U
|
CA |
|
M
|
Magic Software Enterprises Ltd
F:MGK
|
IL |
|
Fomento de Construcciones y Contratas SA
MAD:FCC
|
ES |
|
4
|
4Basebio PLC
F:88Q
|
UK |
|
Action Construction Equipment Ltd
NSE:ACE
|
IN |
|
S
|
Seabridge Gold Inc
F:SRM
|
CA |
|
EVN AG
LSE:0EEI
|
AT |
Wall St Price Targets
PBIGF Price Targets Summary
Paradigm Biopharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for PBIGF is 0.65 USD with a low forecast of 0.64 USD and a high forecast of 0.67 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PBIGF's stock price target?
Price Target
0.65
USD
According to Wall Street analysts, the average 1-year price target for PBIGF is 0.65 USD with a low forecast of 0.64 USD and a high forecast of 0.67 USD.
What is the Revenue forecast for Paradigm Biopharmaceuticals Ltd?
Projected CAGR
179%
Over the last 10 years, the compound annual growth rate for Revenue has been 99%. The projected CAGR for the next 3 years is 179%.
What is the Gross Profit forecast for Paradigm Biopharmaceuticals Ltd?
Projected CAGR
181%
The compound annual growth rate for Gross Profit over the next 3 years is 181%.
